APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Dipeptide Peptidase 4 (DPP-4) Inhibitors

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 173984980320 December 2025188 pages

Choose your research edition.

Industry ResearchDipeptide Peptidase 4 (DPP-4) Inhibitors Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Growth and Trends Forecast to 203298 pages · $3,450 USDMarket StructureGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Dipeptide Peptidase 4 (DPP-4) Inhibitors market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Dipeptide Peptidase 4 (DPP-4) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Dipeptide Peptidase 4 (DPP-4) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Dipeptide Peptidase 4 (DPP-4) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Dipeptide Peptidase 4 (DPP-4) Inhibitors is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Dipeptide Peptidase 4 (DPP-4) Inhibitors include Takeda Pharmaceutical Company, Merck, Eli Lilly, Boehringer Ingelheim, BMS and AstraZenica, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Dipeptide Peptidase 4 (DPP-4) Inhibitors and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Dipeptide Peptidase 4 (DPP-4) Inhibitors sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Dipeptide Peptidase 4 (DPP-4) Inhibitors market size, projected growth trends, production technologies, key applications, and end-use industries.

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Company

Takeda Pharmaceutical Company

Merck

Eli Lilly

Boehringer Ingelheim

BMS

AstraZenica

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Type

Alogliptin

Linagliptin

Sitagliptin

Saxagliptin

Vildagliptin

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Application

Hospitals

Clinics

Dipeptide Peptidase 4 (DPP-4) Inhibitors Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dipeptide Peptidase 4 (DPP-4) Inhibitors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Dipeptide Peptidase 4 (DPP-4) Inhibitors and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dipeptide Peptidase 4 (DPP-4) Inhibitors.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Dipeptide Peptidase 4 (DPP-4) Inhibitors market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Dipeptide Peptidase 4 (DPP-4) Inhibitors manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Dipeptide Peptidase 4 (DPP-4) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Dipeptide Peptidase 4 (DPP-4) Inhibitors in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Trends Table 2. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Drivers Table 3. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Opportunities and Challenges Table 4. Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Restraints Table 5. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Manufacturers Table 9. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Manufacturers, Product Type & Application Table 13. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Alogliptin Table 17. Major Manufacturers of Linagliptin Table 18. Major Manufacturers of Sitagliptin Table 19. Major Manufacturers of Saxagliptin Table 20. Major Manufacturers of Vildagliptin Table 21. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2021-2026) & (K Units) Table 23. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2027-2032) & (K Units) Table 24. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Type (2021-2026) Table 25. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Type (2027-2032) Table 26. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Type (2021-2026) & (K Units) Table 28. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Type (2027-2032) & (K Units) Table 29. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Type (2021-2026) Table 30. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospitals Table 32. Major Manufacturers of Clinics Table 33. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2021-2026) & (K Units) Table 35. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2027-2032) & (K Units) Table 36. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Application (2021-2026) Table 37. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Application (2027-2032) Table 38. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Application (2021-2026) & (K Units) Table 40. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Application (2027-2032) & (K Units) Table 41. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Application (2021-2026) Table 42. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Application (2027-2032) Table 43. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region (2021-2026) & (K Units) Table 45. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Region (2021-2026) Table 46. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026) & (K Units) Table 50. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032) & (K Units) Table 51. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026) & (K Units) Table 53. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2027-2032) & (K Units) Table 60. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Region (2021-2026) Table 64. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Region (2027-2032) Table 65. Takeda Pharmaceutical Company Company Information Table 66. Takeda Pharmaceutical Company Business Overview Table 67. Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 69. Takeda Pharmaceutical Company Recent Development Table 70. Merck Company Information Table 71. Merck Business Overview Table 72. Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 74. Merck Recent Development Table 75. Eli Lilly Company Information Table 76. Eli Lilly Business Overview Table 77. Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 79. Eli Lilly Recent Development Table 80. Boehringer Ingelheim Company Information Table 81. Boehringer Ingelheim Business Overview Table 82. Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 84. Boehringer Ingelheim Recent Development Table 85. BMS Company Information Table 86. BMS Business Overview Table 87. BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 89. BMS Recent Development Table 90. AstraZenica Company Information Table 91. AstraZenica Business Overview Table 92. AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio Table 94. AstraZenica Recent Development Table 95. Key Raw Materials Table 96. Raw Materials Key Suppliers Table 97. Dipeptide Peptidase 4 (DPP-4) Inhibitors Distributors List Table 98. Dipeptide Peptidase 4 (DPP-4) Inhibitors Customers List Table 99. Research Programs/Design for This Report Table 100. Authors List of This Report Table 101. Secondary Sources Table 102. Primary Sources List of Figures Figure 1. Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Image Figure 2. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size (2021-2032) & (US$ Million) Figure 4. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales (2021-2032) & (K Units) Figure 5. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Dipeptide Peptidase 4 (DPP-4) Inhibitors Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Alogliptin Image Figure 9. Linagliptin Image Figure 10. Sitagliptin Image Figure 11. Saxagliptin Image Figure 12. Vildagliptin Image Figure 13. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Type (2021-2032) Figure 16. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Type (2021-2032) Figure 19. Hospitals Image Figure 20. Clinics Image Figure 21. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Application (2021-2032) Figure 24. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Application (2021-2032) Figure 27. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2021-2032) Figure 29. U.S. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2021-2032) Figure 34. Germany Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2021-2032) Figure 41. China Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Country (2021-2032) Figure 49. Brazil Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 60. North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 62. Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Dipeptide Peptidase 4 (DPP-4) Inhibitors Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Dipeptide Peptidase 4 (DPP-4) Inhibitors Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Alogliptin
  • Linagliptin
  • Sitagliptin
  • Saxagliptin
  • Vildagliptin
Applications
  • Hospitals
  • Clinics
Companies covered
  • Takeda Pharmaceutical Company
  • Merck
  • Eli Lilly
  • Boehringer Ingelheim
  • BMS
  • AstraZenica

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market Dynamics
  1. 2.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Trends
  2. 2.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Drivers
  3. 2.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Opportunities and Challenges
  4. 2.4 Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Restraints
3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Manufacturers
  1. 3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Manufacturers (2021-2026)
  3. 3.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Manufacturers, Product Type & Application
  7. 3.7 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Dipeptide Peptidase 4 (DPP-4) Inhibitors Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Dipeptide Peptidase 4 (DPP-4) Inhibitors Tier 1, Tier 2, and Tier 3
4 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Type
  1. 4.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Type Introduction
  2. 4.1.1 Alogliptin
  3. 4.1.2 Linagliptin
  4. 4.1.3 Sitagliptin
  5. 4.1.4 Saxagliptin
  6. 4.1.5 Vildagliptin
  7. 4.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type
  8. 4.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Type (2021-2032)
  10. 4.2.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Type (2021-2032)
  11. 4.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Type
  12. 4.3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Type (2021-2032)
  14. 4.3.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Type (2021-2032)
5 Dipeptide Peptidase 4 (DPP-4) Inhibitors Market by Application
  1. 5.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Clinics
  4. 5.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application
  5. 5.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Application (2021-2032)
  7. 5.2.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Market Share by Application (2021-2032)
  8. 5.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Application
  9. 5.3.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Application (2021-2032)
  11. 5.3.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Application (2021-2032)
6 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region
  1. 6.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region (2021-2032)
  3. 6.2.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Region (2021-2026)
  4. 6.2.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region
  1. 7.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region
  2. 7.1.1 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region (2021-2026)
  4. 7.1.3 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue by Region (2027-2032)
  5. 7.1.4 Global Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue (2021-2032)
  8. 7.2.2 North America Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue (2021-2032)
  11. 7.3.2 Europe Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Dipeptide Peptidase 4 (DPP-4) Inhibitors Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceutical Company
  2. 8.1.1 Takeda Pharmaceutical Company Company Information
  3. 8.1.2 Takeda Pharmaceutical Company Business Overview
  4. 8.1.3 Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceutical Company Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  6. 8.1.5 Takeda Pharmaceutical Company Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Eli Lilly
  14. 8.3.1 Eli Lilly Company Information
  15. 8.3.2 Eli Lilly Business Overview
  16. 8.3.3 Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eli Lilly Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  18. 8.3.5 Eli Lilly Recent Developments
  19. 8.4 Boehringer Ingelheim
  20. 8.4.1 Boehringer Ingelheim Company Information
  21. 8.4.2 Boehringer Ingelheim Business Overview
  22. 8.4.3 Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Boehringer Ingelheim Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  24. 8.4.5 Boehringer Ingelheim Recent Developments
  25. 8.5 BMS
  26. 8.5.1 BMS Company Information
  27. 8.5.2 BMS Business Overview
  28. 8.5.3 BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 BMS Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  30. 8.5.5 BMS Recent Developments
  31. 8.6 AstraZenica
  32. 8.6.1 AstraZenica Company Information
  33. 8.6.2 AstraZenica Business Overview
  34. 8.6.3 AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZenica Dipeptide Peptidase 4 (DPP-4) Inhibitors Product Portfolio
  36. 8.6.5 AstraZenica Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Value Chain Analysis
  2. 9.1.1 Dipeptide Peptidase 4 (DPP-4) Inhibitors Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Dipeptide Peptidase 4 (DPP-4) Inhibitors Production Mode & Process
  6. 9.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Dipeptide Peptidase 4 (DPP-4) Inhibitors Distributors
  9. 9.2.3 Dipeptide Peptidase 4 (DPP-4) Inhibitors Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst